:2149 (15 May 2021) DOI:10.22122/arya.v17i0.2149

One-year survival cohort of patients with reduced ejection fraction heart failure in Iranian population: A single center study

Mahdi Abdollahi-Karizno, Neda Partovi, Vahid Noferesti, Naeem Ravanbakhsh, Toba Kazemi, Saeede Khosravi-Bizhaem

DOI: http://dx.doi.org/10.22122/arya.v17i0.2149


BACKGROUND: Cardiovascular diseases (CVDs) are one of the main concerns of health care systems. The aim of this study was to investigate the most important prognostic factors of heart failure (HF) and their survival outcomes in patients in Birjand, East of Iran.

METHODS: A total of 194 systolic HF patients hospitalized in Birjand Valiasr hospital were followed up for 12 months in 2016, and those with reduced left ventricle ejection fraction
(LVEF < 50%) were included in this study. Kaplan-Meier and Cox proportional hazard analysis were used to determine the association of each factor with events.

RESULTS: The mean age of patients was 68.23 ± 13.40 (27-95) years, and 57.2% (111 out of 194) were women. Mean survival time was 294.7 ± 9.924 days. Pervious history of myocardial infarction (MI) [2.141 (1.101-4.161)] increased the risk of cardiovascular hospitalization. Elevated blood levels of potassium [2.264 (1.438-3.564)] was found to be a risk factor for
all-cause and cardiovascular mortality. Moreover, there was a reverse relationship between body height [0.942 (0.888-0.999)] and cardiovascular death. Patients with opium addiction [4.049 (1.310-12.516)] are at a higher risk of cardiovascular mortality. Lower levels of LDL-C [0.977 (0.960-0.996)] and living in rural areas [3.052 (1.039-8.964)] increased all-cause mortality levels. Lack of pervious history of chronic obstructive pulmonary disease (COPD) decreased cardiovascular hospitalization [0.265 (0.062-1.122)].

CONCLUSION: In our study, serum potassium, LDL-C, and uric acid levels in patients with HF were identified as prognostic factors. The height of patients, which can be an indicator of the functional state of their respiratory system, and the history of COPD were also recognized as prognostic factors. Opium use and rural living were identified as social factors influencing patients' prognosis.


Systolic Heart Failure; Prognostic Factors; Follow-Up Study

Full Text:



Loscalzo J. Harrison's cardiovascular medicine 3/E. New York, NY: McGraw-Hill Education; 2016.

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18(8): 891-975.

Fonarow GC. Refining classification of heart failure based on ejection fraction. JACC Heart Fail 2017; 5(11): 808-9.

Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J. Harrison's principles of internal medicine. New York, NY: McGraw-Hill Education; 2011.

Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: A policy statement from the American Heart Association. Circulation 2011; 123(8): 933-44.

Jan VM, Mushtaq M, Aslam K, Rather H, Aliae MS. Risk and prognostic factors in patients of heart failure. Journal of Indian College of Cardiology 2012; 2(2): 64-74.

Iran Institute for Health Metrics and Evaluation. How is the population forecasted to change? [Online]. [cited 2019]; Available from: URL: http://www.healthdata.org/iran

Callender T, Woodward M, Roth G, Farzadfar F, Lemarie JC, Gicquel S, et al. Heart failure care in low- and middle-income countries: A systematic review and meta-analysis. PLoS Med 2014; 11(8): e1001699.

Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart

J 2007; 28(20): 2539-50.

Ponte ML, Keller GA, Di Girolamo G. Mechanisms of drug induced QT interval prolongation. Curr Drug Saf 2010; 5(1): 44-53.

Fauci A, Kasper D, Loscalzo J, Jameson L, Hauser SL, Longo D. Harrison's principles of internal medicine. New York, NY: McGraw-Hill Education Language; 2018.

Harikrishnan S, Sanjay G, Agarwal A, Kumar NP, Kumar KK, Bahuleyan CG, et al. One-year mortality outcomes and hospital readmissions of patients admitted with acute heart failure: Data from the Trivandrum Heart Failure Registry in Kerala, India. Am Heart J 2017; 189: 193-9.

Goldberg RJ, Ciampa J, Lessard D, Meyer TE, Spencer FA. Long-term survival after heart failure: A contemporary population-based perspective. Arch Intern Med 2007; 167(5): 490-6.

Singh RB, Sharma JP, Rastogi V, Raghuvanshi RS, Moshiri M, Verma SP, et al. Prevalence of coronary artery disease and coronary risk factors in rural and urban populations of north India. Eur Heart J 1997; 18(11): 1728-35.

Tromp J, Ter Maaten JM, Damman K, O'Connor CM, Metra M, Dittrich HC, et al. Serum potassium levels and outcome in acute heart failure (Data from the PROTECT and COACH Trials). Am J Cardiol 2017; 119(2): 290-6.

Desai AS, Liu J, Pfeffer MA, Claggett B, Fleg J, Lewis EF, et al. Incident hyperkalemia, hypokalemia, and clinical outcomes during spironolactone treatment of heart failure with preserved ejection fraction: analysis of the TOPCAT Trial. J Card Fail 2018; 24(5): 313-20.

Aldahl M, Jensen AC, Davidsen L, Eriksen MA, Moller HS, Nielsen BJ, et al. Associations of serum potassium levels with mortality in chronic heart failure patients. Eur Heart J 2017; 38(38): 2890-6.

Patel RB, Tannenbaum S, Viana-Tejedor A, Guo J, Im K, Morrow DA, et al. Serum potassium levels, cardiac arrhythmias, and mortality following non-ST-elevation myocardial infarction or unstable angina: insights from MERLIN-TIMI 36. Eur Heart J Acute Cardiovasc Care 2017; 6(1): 18-25.

Collins AJ, Pitt B, Reaven N, Funk S, McGaughey K, Wilson D, et al. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes. Am J Nephrol 2017; 46(3): 213-21.

Hughes-Austin JM, Rifkin DE, Beben T, Katz R, Sarnak MJ, Deo R, et al. The Relation of Serum Potassium Concentration with Cardiovascular Events and Mortality in Community-Living Individuals. Clin J Am Soc Nephrol 2017; 12(2): 245-52.

McDonald B, Davis RP, Kim SJ, Tse M, Esmon CT, Kolaczkowska E, et al. Platelets and neutrophil extracellular traps collaborate to promote intravascular coagulation during sepsis in mice. Blood 2017; 129(10): 1357–67.

Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Lipoprotein components and risk of congestive heart failure in 84,740 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). Eur J Heart Fail 2009; 11(11): 1036-42.

Ingelsson E, Arnlov J, Sundstrom J, Zethelius B, Vessby B, Lind L. Novel metabolic risk factors for heart failure. J Am Coll Cardiol 2005; 46(11): 2054-60.

Varbo A, Nordestgaard BG. Nonfasting triglycerides, low-density lipoprotein cholesterol, and heart failure risk: Two cohort studies of 113 554 Individuals. Arterioscler Thromb Vasc Biol 2018; 38(2): 464-72.

Velavan P, Huan Loh P, Clark A, Cleland JG. The cholesterol paradox in heart failure. Congest Heart Fail 2007; 13(6): 336-41.

Charach G, Rabinovich A, Ori A, Weksler D, Sheps D, Charach L, et al. Low levels of low-density lipoprotein cholesterol: A negative predictor of survival in elderly patients with advanced heart failure. Cardiology 2014; 127(1): 45-50.

Rauchhaus M, Clark AL, Doehner W, Davos C, Bolger A, Sharma R, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003; 42(11): 1933-40.

Witte KK, Clark AL. Nutritional abnormalities contributing to cachexia in chronic illness. Int J Cardiol 2002; 85(1): 23-31.

Gerber Y, Weston SA, Enriquez-Sarano M, Berardi C, Chamberlain AM, Manemann SM, et al.

Mortality associated with heart failure after myocardial infarction: A contemporary community perspective. Circ Heart Fail 2016; 9(1):


Jackson CE, Haig C, Welsh P, Dalzell JR, Tsorlalis IK, McConnachie A, et al. The incremental prognostic and clinical value of multiple novel biomarkers in heart failure. Eur J Heart Fail 2016; 18(12): 1491-8.

Jacob J, Tost J, Miro O, Herrero P, Martin-Sanchez FJ, Llorens P. Impact of chronic obstructive pulmonary disease on clinical course after an episode of acute heart failure. EAHFE-COPD study. Int J Cardiol 2017; 227: 450-6.

Cuthbert JJ, Kearsley JW, Kazmi S, Kallvikbakka-Bennett A, Weston J, Davis J, et al. The impact of heart failure and chronic obstructive pulmonary disease on mortality in patients presenting with breathlessness. Clin Res Cardiol 2019; 108(2): 185-93.

Sofer T, Moon JY, Isasi CR, Qi Q, Shah NA, Kaplan RC, et al. Relationship of genetic determinants of height with cardiometabolic and pulmonary traits in the Hispanic Community Health Study/Study of Latinos. Int J Epidemiol 2018; 47(6): 2059-69.

Harati H, Shamsi A, Firouzkouhi Moghadam M, Seyed Zadeh FS, Ghazi A. The mortality rate of myocardial infraction patients with and without opium dependen. Int J High Risk Behav Addict 2015; 4(3): e22576.

Khodneva Y, Muntner P, Kertesz S, Kissela B, Safford MM. Prescription Opioid Use and Risk of Coronary Heart Disease, Stroke, and Cardiovascular Death Among Adults from a Prospective Cohort (REGARDS Study). Pain Med 2016; 17(3): 444-55.

Davoodi G, Sadeghian S, Akhondzadeh S, Darvish S, Alidoosti M, Amirzadegan A. Comparison of specifications, short term outcome and prognosis of acute myocardial infarction in opium dependent patients and nondependents. J Tehran Heart Cent 2006; 1(1): 48-53.

Maslov LN, Khaliulin I, Oeltgen PR, Naryzhnaya NV, Pei JM, Brown SA, et al. Prospects for creation of cardioprotective and antiarrhythmic drugs based on opioid receptor agonists. Med Res Rev 2016; 36(5): 871-923.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 4.0

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.